Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by optimi$ticon May 10, 2019 11:06pm
331 Views
Post# 29737012

Big play on the way

Big play on the waybet no one has heard of Chemesis. Check out this reading on them, you will see plenty of APHA connections and all the dots will then connect.

https://thetradingletter.com/thompson-the-warren-buffett-weed-play-company/


f
rom Rapid Dose to Latin America, it seems Vic knew better to capitalize on them. Bigger things are in the works than we stand to see.


Chemesis announced last year that they have come into partnership with Rapid Dose Therapeutics (RDT), a Canadian bio-technology company providing disruptive proprietary drug delivery technologies designed to improve patient outcomes, with a novel proprietary therapeutic delivery system QuickStrip™ Oral Thin Strips to Puerto Rico and California.

At the end of the year, Chemesis International Inc. (OTC:CADMF) (CSI:CSE) made another acquisition and entered into a binding Letter of Intent to acquire 100% of Colombia-based La Finca Interacviva-Arachna Med SAS (La Finca), an integrated cannabis company licensed and operational in Colombia since 2017. La Finca has over 1,000 acres of outdoor cannabis cultivation and is aggressively exploring expansion opportunities throughout the country.

After securing the Puerto Rican and Colombian cannabis markets, CFN Media Group -- the leading agency and financial network of the North American cannabis industry -- published an article calling out the emerging Latin American market and specifically recognized Chemesis Latin America, Chemesis International’s new subsidiary, focusing on their disruption of Central and South American cannabis markets.

Along with their Latin American acquisition, Chemesis International has obtained a full line of CBD products, which are for sale in the U.S. Their Viverian line of CBD products are available for purchase in Arizona, Nevada, and Florida. The products are lab tested, THC free, and made of 100% botanical ingredients, all manufactured from a third party GMP certified facility.

Bullboard Posts